Back to search
FDAFDA · Food and drugs·Recall number D-1039-2018

Valsartan/HCTZ 320/25mg Tablets, 30-count jar, Rx Only, Packaged by NuCare Pharmaceuticals, Inc., Orange, CA 92867, NDC 68071-4183-3

Published August 15, 2018 · Recall initiated: July 30, 2018

Summary

FDA records drug Class II recall D-1039-2018, published August 15, 2018 and initiated July 30, 2018. Recalling firm: NuCare Pharmaceuticals Inc; Status: Terminated; Reported quantity: N/A; Lot: Lot # T11577; Exp. 06/30/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
NuCare Pharmaceuticals Inc
Distributor
Distributed to three customers in Fl and CA
Lot
Lot # T11577; Exp. 06/30/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Valsartan/HCTZ 320/25mg Tablets, 30-count jar, Rx Only, Packaged by NuCare Pharmaceuticals, Inc., Orange, CA 92867, NDC 68071-4183-3 recalled?

Yes. FDA published recall D-1039-2018 on August 15, 2018. Reported hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter